Cristina Gonzalez-Calvo

Madrid, MD 28040, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
Published: June 20, 2021

Assessment of the perception of healthcare barriers and the impact of intravitreal injections on neovascular age-related macular degeneration.

Assessment of the perception of healthcare barriers and the impact of intravitreal injections on neovascular age-related macular degeneration.

Journal: Archivos de la Sociedad Espanola de Oftalmologia
Published: October 12, 2020

Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration.

Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration.

Journal: Archivos de la Sociedad Espanola de Oftalmologia
Published: September 21, 2020

Congenital retinal macrovessels: Case presentation.

Congenital retinal macrovessels: Case presentation.

Journal: Archivos de la Sociedad Espanola de Oftalmologia
Published: April 21, 2020

Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.

Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.

Journal: International ophthalmology
Published: October 29, 2018

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization.

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
Published: February 21, 2017

Arteriovenous malformation of the iris. Two cases.

Arteriovenous malformation of the iris. Two cases.

Journal: Archivos de la Sociedad Espanola de Oftalmologia
Published: March 27, 2015

Posterior pole arterial vascular variant

Posterior pole arterial vascular variant

Journal: Journal francais d'ophtalmologie
Published: February 15, 2015

Double cilioretinal artery

Double cilioretinal artery

Journal: Journal francais d'ophtalmologie
Published: February 04, 2015

Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.

Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.

Journal: Investigative ophthalmology & visual science
Published: August 24, 2012

Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.

Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.

Journal: European journal of ophthalmology
Published: February 28, 2011

Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy

Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy

Journal: Archivos de la Sociedad Espanola de Oftalmologia
Published: September 23, 2010
Showing 1-12 of 22

Last Updated: 09/26/2026